HOME >> BIOLOGY >> NEWS
The PSA bounce Does it have clinical significance?

Using the largest known prostate cancer data set of patients treated solely with external-beam radiation in the U.S., radiation oncologists have examined the "PSA bounce" phenomenon and determined that it is not an indicator that men will die of prostate cancer any sooner than those men who do not experience a bounce. That is the result of a multi-institutional analysis presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Atlanta, Ga.

The PSA (prostate-specific antigen) test is a blood test used for routine prostate cancer screening. The "PSA bounce" is a rise and then decline in the PSA level following radiation treatment for prostate cancer. The bounce phenomenon occurs in a third to half of men treated with radiation for prostate cancer. Urologists, radiation and medical oncologists have struggled with what a bouncing PSA means for a patient's prognosis, and how or if to offer further treatment.

"Because a steady rise in PSA can mean that cancer has recurred, physicians often interpret a bounce as the possibility that the cancer may still exist after treatment," explained Eric M. Horwitz, M.D., clinical director of the radiation oncology department at Fox Chase Cancer Center and lead author of the study. "Some physicians prescribe hormonal therapy in this situation, but hormones can have significant side effects for the patient, and may not be clinically necessary. For these reasons, it's important to develop clear guidelines."

In this retrospective analysis, data were gathered from the records of 4,839 men treated only with external-beam radiation between 1986 and 1995 at nine institutions throughout the US. The median follow-up was 6.3 years. Treatment during this time period consisted primarily of conventional radiation therapy, a lower dose than is generally used at academic cancer centers today, although some patients were treated with 3D conformal radiation therapy. In thi
'"/>

Contact: Colleen Kirsch
colleen.kirsch@fccc.edu
215-306-1211
Fox Chase Cancer Center
6-Oct-2004


Page: 1 2

Related biology news :

1. HIV-1 kills immune cells in the gut that may never bounce back
2. Phytoplankton bounce back from abrupt climate change
3. Fat kids can bounce back to normal blood pressure
4. Preclinical study links gene to brain aneurysm formation
5. Gene variant is associated with brain anatomy, clinical course of ADHD
6. New joint replacement material developed at MGH put to first clinical use
7. Serica scientists win AOSSM Award for ACL (knee) tissue regeneration in preclinical study
8. From clinical cancer research: rethinking therapeutic cancer vaccine trials
9. Manganese levels increase in scrapie-infected sheep before clinical symptoms develop
10. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
11. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The PSA bounce Does have clinical significance

(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is ... newest office in Charlottetown , PEI.  ... Prince Edward Island ADAPT Council for the commercialization of ... forward to working with PEI ADAPT.  They have been ... more than a decade," explains Dave Smardon , ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., a ... therapeutic antibodies, today announced the advancement of ... into IND-enabling studies. The Company,s anti-IL-36R therapeutic ... for generalized pustular psoriasis (GPP), an orphan ... need. ANB019 is wholly owned within AnaptysBio,s proprietary ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... Fairleigh Dickinson University ( FDU ... become the Executive Director of the Rothman Institute ... kick-off of the Initiative for Patient Centered Innovation ... under the Rothman Institute of Innovation and Entrepreneurship ... collaboration with FDU’s School of Pharmacy’s Center for ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
Cached News: